darapladib and Hypercholesterolemia

darapladib has been researched along with Hypercholesterolemia* in 3 studies

Other Studies

3 other study(ies) available for darapladib and Hypercholesterolemia

ArticleYear
Retinal pathology is associated with increased blood-retina barrier permeability in a diabetic and hypercholesterolaemic pig model: Beneficial effects of the LpPLA
    Diabetes & vascular disease research, 2017, Volume: 14, Issue:3

    Using a porcine model of diabetes mellitus and hypercholesterolaemia, we previously showed that diabetes mellitus and hypercholesterolaemia is associated with a chronic increase in blood-brain barrier permeability in the cerebral cortex, leading to selective binding of immunoglobulin G and deposition of amyloid-beta

    Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Animals; Anti-Inflammatory Agents; Benzaldehydes; Blood-Brain Barrier; Blood-Retinal Barrier; Capillary Permeability; Claudin-5; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Gliosis; Hypercholesterolemia; Immunoglobulin G; Male; Occludin; Oximes; Phospholipase A2 Inhibitors; Protein Binding; Retinal Ganglion Cells; Sus scrofa

2017
Atherosclerotic plaque inflammation varies between vascular sites and correlates with response to inhibition of lipoprotein-associated phospholipase A2.
    Journal of the American Heart Association, 2015, Feb-11, Volume: 4, Issue:2

    Despite systemic exposure to risk factors, the circulatory system develops varying patterns of atherosclerosis for unclear reasons. In a porcine model, we investigated the relationship between site-specific lesion development and inflammatory pathways involved in the coronary arteries (CORs) and distal abdominal aortas (AAs).. Diabetes mellitus (DM) and hypercholesterolemia (HC) were induced in 37 pigs with 3 healthy controls. Site-specific plaque development was studied by comparing plaque severity, macrophage infiltration, and inflammatory gene expression between CORs and AAs of 17 DM/HC pigs. To assess the role of lipoprotein-associated phospholipase A2 (Lp-PLA2) in plaque development, 20 DM/HC pigs were treated with the Lp-PLA2 inhibitor darapladib and compared with the 17 DM/HC untreated pigs. DM/HC caused site-specific differences in plaque severity. In the AAs, normalized plaque area was 4.4-fold higher (P<0.001) and there were more fibroatheromas (9 of the 17 animals had a fibroatheroma in the AA and not the COR, P=0.004), while normalized macrophage staining area was 1.5-fold higher (P=0.011) compared with CORs. DM/HC caused differential expression of 8 of 87 atherosclerotic genes studied, including 3 important in inflammation with higher expression in the CORs. Darapladib-induced attenuation of normalized plaque area was site-specific, as CORs responded 2.9-fold more than AAs (P=0.045).. While plaque severity was worse in the AAs, inflammatory genes and inflammatory pathways that use Lp-PLA2 were more important in the CORs. Our results suggest fundamental differences in inflammation between vascular sites, an important finding for the development of novel anti-inflammatory therapeutics.

    Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Animals; Aorta, Abdominal; Atherosclerosis; Benzaldehydes; Coronary Vessels; Diabetes Mellitus; Disease Models, Animal; Gene Expression; Hypercholesterolemia; Inflammation; Macrophages; Male; Oximes; Phospholipase A2 Inhibitors; Plaque, Atherosclerotic; Swine

2015
Diabetes and hypercholesterolemia increase blood-brain barrier permeability and brain amyloid deposition: beneficial effects of the LpPLA2 inhibitor darapladib.
    Journal of Alzheimer's disease : JAD, 2013, Volume: 35, Issue:1

    Diabetes mellitus (DM) and hypercholesterolemia (HC) have emerged as major risk factors for Alzheimer's disease, highlighting the importance of vascular health to normal brain functioning. Our previous study showed that DM and HC favor the development of advanced coronary atherosclerosis in a porcine model, and that treatment with darapladib, an inhibitor of lipoprotein-associated phospholipase A2, blocks atherosclerosis progression and improves animal alertness and activity levels. In the present study, we examined the effects of DM and HC on the permeability of the blood-brain barrier (BBB) using immunoglobulin G (IgG) as a biomarker. DMHC increased BBB permeability and the leak of microvascular IgG into the brain interstitium, which was bound preferentially to pyramidal neurons in the cerebral cortex. We also examined the effects of DMHC on the brain deposition of amyloid peptide (Aβ42), a well-known pathological feature of Alzheimer's disease. Nearly all detectable Aβ42 was contained within cortical pyramidal neurons and DMHC increased the density of Aβ42-loaded neurons. Treatment of DMHC animals with darapladib reduced the amount of IgG-immunopositive material that leaked into the brain as well as the density of Aβ42-containing neurons. Overall, these results suggest that a prolonged state of DMHC may have chronic deleterious effects on the functional integrity of the BBB and that, in this DMHC pig model, darapladib reduces BBB permeability. Also, the preferential binding of IgG and coincident accumulation of Aβ42 in the same neurons suggests a mechanistic link between the leak of IgG through the BBB and intraneuronal deposition of Aβ42 in the brain.

    Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Amyloid beta-Peptides; Animals; Benzaldehydes; Blood-Brain Barrier; Brain; Capillary Permeability; Diabetes Mellitus; Hypercholesterolemia; Oximes; Peptide Fragments; Random Allocation; Rats; Rats, Sprague-Dawley; Swine; Treatment Outcome

2013